Search results for

The sheer volume of loss felt by the music world in 2020 is almost overwhelming. Here is NPR's tribute to dozens of the musicians — founders and innovators across genres — who died this year.

Aaron Glantz is a senior investigative reporter at Reveal from The Center for Investigative Reporting and Pulitzer Prize finalist. His new book examines how members of President Trump's inner circle bet big after the housing bust and made billions of dollars keeping the American Dream out of reach for individual families.

Beyoncé's Africa video, Inuit advice on raising kids without yelling and ... locusts! Here's the surprising mix of stories Goats and Soda readers loved in 2020 that have nothing to do with COVID-19.

The New York Times issued a big mea culpa, and returned a Peabody award and a citation as a finalist for the Pulitzer Prize after retracting the core of its hit podcast series Caliphate.

Sunday, Sept. 8, 2024 at 9:30 p.m. on KPBS TV / Stream now with the PBS app. An unvarnished look at the unlikely LITTLE HOUSE series author whose autobiographical fiction helped shape American ideas of the frontier and self-reliance.

As California Gov. Gavin Newsom weighs his pick to serve out the rest of Vice President-elect Kamala Harris' Senate term, he's facing pressure to name a Latino or a Black woman. California has never had a Latino senator even though the state is nearly 40% Latino.

After an internal review, The New York Times now says it built the 2018 podcast Caliphate on a story it cannot vouch for. It says star reporter Rukmini Callimachi will no longer cover terrorism.

Many favorite holiday traditions could be treacherous this year because of the coronavirus. Here's how experts view the risks — and some creative, safer alternatives to keep up a festive mood.

Many favorite holiday traditions could be treacherous this year because of the coronavirus. Here's how experts view the risks — and some creative, safer alternatives to keep up a festive mood.

As the first patient to receive an experimental treatment that relied on the gene-editing technique CRISPR continues to do well 17 months later, more patients seem to be benefiting, too.